ArriVent reports FY2024 net loss $80.5M; cash $266.5M; Phase 3 trial enrollment achieved

ArriVent BioPharma, Inc.

Cash and investments of $266.5M as of Dec 31, 2024; expected to fund operations into 2026.
Net loss $80.5M for FY2024 vs $69.3M in FY2023; R&D expense $79.0M.
Global pivotal Phase 3 FURVENT study for firmonertinib in EGFR exon20ins NSCLC reached target enrollment of 375 patients.
Selected next-generation ADC candidate ARR-002 for IND-enabling studies; in-licensed ARR-217 (MRG007) from Lepu Biopharma.
Plan to provide update on firmonertinib in EGFR PACC mutant NSCLC in H1 2025; top-line Phase 3 data expected in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.